Follow us on Twitter
twitter icon@FreshPatents

Elan patents

Bulk PDF Downloads
      

This page is updated frequently with new Elan-related patent applications.




 C2i (consume to invest) stock ownership program patent thumbnailnew patent C2i (consume to invest) stock ownership program
As our economy evolves and the labor marketplace consists increasingly of freelance workers, the corporate shareholder ownership program could be extended to freelancers. Instead of receiving all of their compensation from multiple ‘employers’ in cash, freelancers could choose to be paid by some corporations for which they perform work with stock in the relevant company..

 Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma patent thumbnailnew patent Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.. .
Castle Biosciences, Inc.


 Inhibition of a lncrna for treatment of melanoma patent thumbnailnew patent Inhibition of a lncrna for treatment of melanoma
This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding rna (lncrna) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes.
Universiteit Gent


 Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness patent thumbnailTyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target tyrp1 rna transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents.
Centre Hospitalier Universitaire Pontchaillou


 Antibodies for treatment of cancer expressing claudin 6 patent thumbnailAntibodies for treatment of cancer expressing claudin 6
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing cldn6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.. .
Johannes Gutenberg-universitat Mainz


 Pyrrolo pyrimidine derivative patent thumbnailPyrrolo pyrimidine derivative
A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases..
Ono Pharmaceutical Co., Ltd.


 Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) patent thumbnailPolycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


 Heteromaromatic compounds useful for the treatment of prolferative diseases patent thumbnailHeteromaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of formula (i) and formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.


 Heteroaromatic compounds useful for the treatment of prolferative diseases patent thumbnailHeteroaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


 Pharmaceutical compositions and methods patent thumbnailPharmaceutical compositions and methods
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3a4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3a4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
Tyme, Inc.


T cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof


The technology relates in part to compositions and methods for inducing an immune response against the preferentially expressed antigen of melanoma (prame). Provided are methods for treating hyperproliferative diseases by inducing an immune response against prame antigen; the immune response may be induced by specifically targeting prame-expressing cells using t cell receptors directed against prame..
Leiden University Medical Center


Pharmaceutical compositions and methods


Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3a4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3a4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
Tyme, Inc.


Topical compositions and methods for skin lightening


Embodiments of the invention are generally directed to compositions useful for reducing pigmentation in the skin. The composition may further include other depigmenting agents such as nicotinamide and its melanasome transfer-inhibiting derivatives, 3,3′-thiodipropanoic acid and its tyrosinase-inhibiting derivatives, or resorcinol and its tyrosinase-inhibiting derivatives, in a topically acceptable vehicle..
Avon Products Inc.


Topical compositions and methods for skin lightening


Embodiments of the invention are generally directed to compositions useful for reducing histamine-induced pigmentation in the skin. The composition may further include other depigmenting agents such as nicotinamide and its melanasome transfer-inhibiting derivatives, 3,3′-thiodipropanoic acid and its tyrosinase-inhibiting derivatives, or resorcinol and its tyrosinase-inhibiting derivatives, in a cosmetically acceptable vehicle..
Avon Products, Inc.


Melanopic lamp


A lamp having a first light source for producing a light having a spectral distribution, wherein the light is represented by a set of chromaticity coordinates in a chromaticity diagram, and having a second light source for producing a second light having a second spectral distribution, wherein the second light is represented by a second set of coordinates in the chromaticity diagram, the second spectral distribution being different from the first spectral distribution. Furthermore, the lamp has a control unit for controlling the light sources, which control unit is designed so that an intensity of the first light can be changed independently of an intensity of the second light.
Zumtobel Lighting Gmbh


Method for treating a subterranean formation


A method of treating a subterranean formation at temperatures of at least 150° c. Is disclosed.
Api Institute


Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof


Dual function compounds are provided that may be inhibitors of histone deacetylase (hdac) and activators of ataxia telangiectasia mutated (atm). Pharmaceutical compositions and methods of use are also provided that utilize such compounds..
Shuttle Pharmaceuticals, Llc


Combination therapy


The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo [2,3-b] pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the v600e b-raf mutation..
Hoffmann-la Roche Inc.


Molding and anchoring physically constrained virtual environments to real-world environments


An “anchored environment generator” generates a physically constrained virtual environment that is molded and anchored to a real-world environment around a user (or multiple users). This molding and anchoring of the physically constrained virtual environment ensures that at least a portion of the physically constrained virtual environment matches tactile truth for one or more surfaces and objects within the real-world environment.
Microsoft Technology Licensing, Llc


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use


Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 (pt1989 atr), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors.
The United States Of America, As Represented By The Secretary, Department Of Health And Human...


Method of treating a malignancy in a subject and a pharmaceutical composition for use in same


There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the picornaviridae family.
Viralytics Limited


Pkc delta inhibitors for use as therapeutics


The invention is directed to compounds that are specific inhibitors of pkc delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers.

Targeted capsules for the delivery of skin whitening agents in the skin


The present invention relates to targeted microcapsules or nanocapsules comprising a skin whitening compound to target melanocytes with a peptide, which is a mc1 receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule or nanocapsule. It also relates to the use of said microcapsules or nanocapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous dark spots, and to the cosmetic compositions comprising said microcapsules or nanocapsules.
Peptidepharma Nova, S.l.


Biocampatible polymer coated silver prussian blue nanoparticles (spb-nps: ag3 [fe (cn) 6])


The present invention relates to highly biocompatible or nontoxic pvp (poly(n-vinyl-2-pyrrolidone) coated silver prussian blue nanoparticles (spb-nps: ag3[fe(cn)6] where pvp acts as stabilizing or capping agent. The as-synthesized nanoparticles (spb-nps) have been thoroughly characterized by several analytical tools.
Council Of Scientific & Industrial Research


Skin lightening composition


Desired skin colour is a major unmet consumer need around the world and especially in asia. Consumers particularly desire even skin colour, absence of age spots (solar lentigines), absence of hyperpigmentation and lighter overall skin tone.
Conopco, Inc., D/b/a Unilever


Graphical user interface with intelligent icons


A system for signaling coordinated workers in a common goal through intelligent icons transferred across networks to computer screens. The system can comprise one or more electronic data processors.
Synabee, Inc


Histamine-3 receptor antagonists


The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i; and a method of treatment of a disorder or condition selected from the list consisting of acute myocardial infarction; memory processes disorders; dementia; cognition disorders such as alzheimer's disease; attention deficit disorder (add); attention-deficit hyperactivity disorder (adhd); cancers such as cutaneous carcinoma, medullary thyroid carcinoma and melanoma; meniere's disease; gastrointestinal disorders; inflammation; migraine; motion sickness; obesity; pain; septic shock; respiratory disorders (including allergic rhinitis, nasal congestion and allergic congestion) in a mammal, including a human, that may be effected by administering to said mammal a pharmacologically effective amount of a compound of formula i, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.. .
Medisynergics, Llc


Method for making anion exchange and chelant resins including aliphatic amino functional groups


A method for making an anion exchange or chelant resin comprising a vinyl aromatic polymer including a repeating unit comprising an aromatic ring substituted with an aliphatic amino group, wherein the method comprises the step of reacting a vinyl aromatic polymer with a nitro compound comprising from 1 to 12 carbon atoms with the proviso that the a carbon includes at least one hydrogen.. .
Dow Global Technologies Llc


Methods of inducing melanogenesis in a subject


Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-msh analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors..
Clinuvel Pharmaceuticals Limited


Stem cell microparticles and mirna


This invention relates to stem cell microparticles and mirna isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer.
Reneuron Limited


Melanin binding agents for targeted topical delivery


Compositions and methods are disclosed for targeted delivery of a benefit agent to areas of a human integument having melanin deposits. The compositions comprise a pyridinium compound having affinity for melanin.
Avon Products, Inc


Low ph metal-free preparation of aminated organic acid


Where r1, r1a, r2, r2a, r3 and r3a are defined as set forth in the specification. Formula i compounds are useful as chelants and stabilizers of cations in aqueous media and the invention therefore provides a method for using the compounds in the treatment of subterranean formations, such as in acidizing operations..

Treatment of melanoma with interferon-beta and ras-raf-mek-erk inhibitor combination therapy


This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies.. .
Biogen Ma Inc.


Method for improving skin condition or anti-microorganisms or anti-oxidation using lactobacillus sakei md honeysuckle


The present disclosure discloses a method for improving the skin condition or anti-microorganisms or anti-oxidation using lactobacillus sakei md_honeysuckle (accession number: kctc 12675bp) derived from lonicera japonica thunb. A composition containing the strain or a cultured product thereof, or an extract thereof as an active ingredient has superior dpph radical scavenging activity and antimicrobial activity against pathogenic microorganisms, has a high total polyphenol content and is capable of inhibiting the growth of melanocytes.
Amorepacific Corporation


Rock in combination with mapk pathway


The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer.
Stichting Het Nederlands Kanker Instituut


Methods of treating melanoma


Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.. .
Abraxis Bioscience, Llc


Method of quantifying melanin mass density in vivo


A method of quantifying melanin includes receiving at a data processor optical data produced by an optical sensor which receives a light from a tissue; determining a set of intensity values based on the optical data; for each intensity value, converting the intensity value to a quantifying value corresponding to quantity of melanin in the tissue based on a two-dimensional non-linear regression with one variable representing the intensity value and another variable representing the quantity of melanin; collecting at the data processor each quantifying value; generating at the data processor melanin quantity distribution data according to the quantifying values; and outputting the melanin quantity distribution data to be presented on a medium.. .
National Taiwan University


Activities of multiple cancer-related pathways are associated with braf mutation and predict the resistance to braf/mek inhibitors in melanoma cells


The present inventors have identified specific oncogenic pathways preferentially activated in braf-mutated-melanoma cells and a pathway pattern that predicts resistance of braf-mutated melanoma to braf/mek inhibitors, providing novel clinical implications for melanoma therapy. In one embodiment, a method comprises (a) testing a sample oibraf-mutated melanoma cells isolated from a patient and measuring the expression levels of genes expressed in the following oncogenic pathways: tnfa, egfr, ifna, hypoxia, ifny, stat3 and myc; (b) calculating a 7-pathway activation pattern based on the measured expression levels of step (a); and (c) identifying the patient's resistance level to braf/mek inhibitor treatment based on comparison of the calculated 7-pathway activation pattern to a reference..
The Johns Hopkins University


Method for enucleating nucleated erythrocyte, and enucleation inducer


Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (pomc) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound..
Kanazawa Medical University


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Antibodies specific for claudin 6 (cldn6)


The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin-6 (cldn6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.. .
Johannes Gutenberg-universitat Mainz


Epidithiodioxopiperazine compound or its derivatives, and the use thereof


The present invention relates to an epidithiodioxopiperazine derivative represented by the following chemical formula 1 or its reduced derivative; a method for preparing a compound represented by chemical formula 1 having improved intracellular permeability and mimicking the activity of 2-cys-prx in its reduced form in the cells; a pharmaceutical composition for preventing or treating vascular diseases comprising an epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient; a drug delivery device for local administration including the pharmaceutical composition; and a pharmaceutical composition for inhibiting melanoma metastasis comprising the epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient.. .
Ewha University-industry Collaboration Foundation


Cosmetic or dermatological use of an extract of tapirira guianensis


Finally, it relates to a tapirira guianensis extract or a dermatological composition comprising a tapirira guianensis extract and a dermatologically acceptable excipient for use by the topical route in the treatment and/or prevention of rosacea, telangiectasia and/or pathologies of the oral and/or ocular mucous membranes.. .

E2f reporter melanoma cells


A modified melanoma cell line capable of quantification of the effects of mek inhibitors and cdk4/6 inhibitors in a quantitative, temporal and non-invasive manner both in vitro and in vivo.. .
Thomas Jefferson University


Method for preparing pluripotent stem cells


An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation. The cells having pluripotency and a very low risk of tumorigenic transformation can be prepared by suspension-culturing mammalian mesenchymal stem cells such as human mesenchymal stem cells from bone marrow (hmsc-bm) and human adipose tissue-derived mesenchymal stem cells (hat-msc) (also referred to as “human adipose-derived stem cells [hadsc]”), 7 types of human adherent mature cells (human hepatocyte cells [hhep cells], human umbilical vein endothelial cells [huvec cells], human dermal lymphatic microvascular endothelial cells [hmvec cells], human epidermal keratinocyte cells [nhek cells], human bronchial epithelial cells [nhbe cells], human melanocyte cells [nhem cells], and human smooth muscle cells [uasmc cells]), and 3 types of human adherent precursor cells (human dermal fibroblast cells [nhdf cells], human skeletal muscle myoblast cells [hsmm cells], and human osteoblast cells [nhost cells]) to form cell masses (spheroids)..
Otsuka Pharmaceutical Factory, Inc.


Multimeric il-15 soluble fusion molecules and methods of making and using same


The present invention features compositions and methods featuring alt-803, a complex of an interleukin-15 (il-15) superagonist mutant and a dimeric il-15 receptor α/fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).. .
Altor Bioscience Corporation


Optical imaging or spectroscopy systems and methods


Optical imaging or spectroscopy described can use laminar optical tomography (lot), diffuse correlation spectroscopy (dcs), or the like. An incident beam is scanned across a target.
The Trustees Of Columbia University In The City Of New York


Systems and methods for crowdsourcing technology projects


The technology introduced here enables a customer to readily view, and securely connect with, project managers and freelancers who complete projects on behalf of the customer. The customer initially posts a project specification through a crowdsourcing platform.
Crowdplat


Antibodies to endoplasmin and their use


Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human.
University Of Pittsburgh - Of The Commonwealth Sys Tem Of Higher Education


Heteroaryl amides as inhibitors of protein aggregation


The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as parkinson's disease, alzheimer's disease, lewy body disease, parkinson's disease with dementia, fronto-temporal dementia, huntington's disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.. .
Neuropore Therapies, Inc.




Elan topics:
  • Folic Acid
  • Carbon Dioxide
  • Antibodies
  • Immune Response
  • High Energy
  • Inorganic Compounds
  • Electrolysis
  • Semiconductor Material
  • Semiconductor
  • Hydrogen Production From Water
  • Female Sexual Dysfunction
  • Dysfunction
  • Sexual Dysfunction
  • Mammography
  • Radiograph


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Elan for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7966

    4395

    0 - 1 - 101